Clinical Trial ProgressALMS remains on track to report topline data from the Phase 3 ONWARD program of lead asset envudeucitinib in plaque psoriasis, in line with prior guidance.
Efficacy And Safety ProfileALMS is aiming to demonstrate a profile competitive on efficacy and safety to other Phase 3 advanced oral therapies, with an advantage on convenience, as envu has no food effect and does not require fasting.
Market PositioningManagement’s emphasis on simplicity, lack of prior authorization hurdles, favorable COGS, and a planned QD formulation option bolster its commercial positioning.